CDKL5 Deficiency Disorder

Our mission: Fight for children with CDKL5 Deficiency Disorder and their families.

At Marinus, we ally with our healthcare partners and advocacy groups because we care about our patients’ lives, stories, and voices.

What is CDKL5 Deficiency Disorder?

CDKL5 deficiency disorder (CDD) is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, which is located on the X chromosome and encodes proteins essential for normal brain function. CDD predominantly affects females and is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. Many children diagnosed with CDD also experience scoliosis, visual impairment, sensory problems, gastrointestinal difficulties, and sleeping disorders.

Expanded Access Program

Marinus launched the Expanded Access Program (EAP) for CDKL5 in January 2020.
This program allows qualified patients to receive the investigational drug ganaxolone for CDD.


It is estimated that there are 90 – 100 babies born with CDD in the U.S. every year.

Young Girl Teddy Heart Physician

Learn more about CDKL5 deficiency disorder

Additional educational and support resources:

International Foundation for CDKL5 Research

CDKL5 Alliance

CDKL5 Research Collaborative

Loulou Foundation

Hope4Harper

Links to third party sites are provided for convenience purposes only. The information contained on these sites is not information provided, controlled or monitored by Marinus Pharmaceuticals in any way. Marinus Pharmaceuticals is not responsible in any way for the accuracy, completeness, or fitness for any particular purpose of any content appearing on such sites.

Partridge Family Cdlk5 1

Patient Story:

CDKL5 Deficiency Disorder: Partridge Family